BR9807112A - Composição, formulação farmacêutica, combinação e uso relacionados ao tratamento de doenças autoimunes utilizando antìgeno ou agente tolerante em combinação com metotrexato - Google Patents

Composição, formulação farmacêutica, combinação e uso relacionados ao tratamento de doenças autoimunes utilizando antìgeno ou agente tolerante em combinação com metotrexato

Info

Publication number
BR9807112A
BR9807112A BR9807112-2A BR9807112A BR9807112A BR 9807112 A BR9807112 A BR 9807112A BR 9807112 A BR9807112 A BR 9807112A BR 9807112 A BR9807112 A BR 9807112A
Authority
BR
Brazil
Prior art keywords
combination
antigen
methotrexate
pharmaceutical formulation
treatment
Prior art date
Application number
BR9807112-2A
Other languages
English (en)
Portuguese (pt)
Inventor
Howard L Weiner
Ahmad Al-Sabbagh
Patricia A Nelson
Original Assignee
Autoimmune Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Autoimmune Inc filed Critical Autoimmune Inc
Publication of BR9807112A publication Critical patent/BR9807112A/pt

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
    • A61K31/519—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim ortho- or peri-condensed with heterocyclic rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/0005—Vertebrate antigens
    • A61K39/0008—Antigens related to auto-immune diseases; Preparations to induce self-tolerance
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/04—Drugs for skeletal disorders for non-specific disorders of the connective tissue
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00—Drugs for disorders of the senses
    • A61P27/02—Ophthalmic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
    • A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A61P37/06—Immunosuppressants, e.g. drugs for graft rejection
    • B—PERFORMING OPERATIONS; TRANSPORTING
    • B41—PRINTING; LINING MACHINES; TYPEWRITERS; STAMPS
    • B41J—TYPEWRITERS; SELECTIVE PRINTING MECHANISMS, i.e. MECHANISMS PRINTING OTHERWISE THAN FROM A FORME; CORRECTION OF TYPOGRAPHICAL ERRORS
    • B41J2/00—Typewriters or selective printing mechanisms characterised by the printing or marking process for which they are designed
    • B41J2/005—Typewriters or selective printing mechanisms characterised by the printing or marking process for which they are designed characterised by bringing liquid or particles selectively into contact with a printing material
    • B41J2/01—Ink jet
    • B41J2/21—Ink jet for multi-colour printing
    • B41J2/2107—Ink jet for multi-colour printing characterised by the ink properties
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/54—Medicinal preparations containing antigens or antibodies characterised by the route of administration
    • A61K2039/541—Mucosal route
    • A61K2039/542—Mucosal route oral/gastrointestinal
    • G—PHYSICS
    • G06—COMPUTING; CALCULATING OR COUNTING
    • G06K—GRAPHICAL DATA READING; PRESENTATION OF DATA; RECORD CARRIERS; HANDLING RECORD CARRIERS
    • G06K2215/00—Arrangements for producing a permanent visual presentation of the output data
    • G06K2215/0082—Architecture adapted for a particular function
    • G06K2215/0094—Colour printing
    • G—PHYSICS
    • G06—COMPUTING; CALCULATING OR COUNTING
    • G06K—GRAPHICAL DATA READING; PRESENTATION OF DATA; RECORD CARRIERS; HANDLING RECORD CARRIERS
    • G06K2215/00—Arrangements for producing a permanent visual presentation of the output data
    • G06K2215/0082—Architecture adapted for a particular function
    • G06K2215/0097—Printing on special media, e.g. labels, envelopes

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Chemical & Material Sciences (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Animal Behavior & Ethology (AREA)
  • Engineering & Computer Science (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Organic Chemistry (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Immunology (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Diabetes (AREA)
  • Epidemiology (AREA)
  • Rheumatology (AREA)
  • Microbiology (AREA)
  • Mycology (AREA)
  • Ophthalmology & Optometry (AREA)
  • Endocrinology (AREA)
  • Pain & Pain Management (AREA)
  • Emergency Medicine (AREA)
  • Transplantation (AREA)
  • Biomedical Technology (AREA)
  • Physical Education & Sports Medicine (AREA)
  • Obesity (AREA)
  • Hematology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
BR9807112-2A 1997-01-24 1998-01-26 Composição, formulação farmacêutica, combinação e uso relacionados ao tratamento de doenças autoimunes utilizando antìgeno ou agente tolerante em combinação com metotrexato BR9807112A (pt)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US3672297P 1997-01-24 1997-01-24
PCT/US1998/001648 WO1998032451A1 (en) 1997-01-24 1998-01-26 Treatment of autoimmune disease using tolerization in combination with methotrexate

Publications (1)

Publication Number Publication Date
BR9807112A true BR9807112A (pt) 2001-09-18

Family

ID=21890248

Family Applications (1)

Application Number Title Priority Date Filing Date
BR9807112-2A BR9807112A (pt) 1997-01-24 1998-01-26 Composição, formulação farmacêutica, combinação e uso relacionados ao tratamento de doenças autoimunes utilizando antìgeno ou agente tolerante em combinação com metotrexato

Country Status (10)

Country Link
EP (1) EP0994717A4 (ja)
JP (1) JP2001511134A (ja)
KR (1) KR20000070460A (ja)
AU (1) AU6648898A (ja)
BR (1) BR9807112A (ja)
CA (1) CA2278152A1 (ja)
HU (1) HUP0001960A2 (ja)
IL (1) IL131025A0 (ja)
NO (1) NO993600L (ja)
WO (1) WO1998032451A1 (ja)

Families Citing this family (21)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
ATE409057T1 (de) 2002-02-11 2008-10-15 Antares Pharma Inc Intradermales injektionsgerät
WO2006079064A1 (en) 2005-01-24 2006-07-27 Antares Pharma, Inc. Prefilled needle assisted jet injector
GB0523576D0 (en) * 2005-11-18 2005-12-28 Theradeas Ltd Drug composition and its use in therapy
US8251947B2 (en) 2006-05-03 2012-08-28 Antares Pharma, Inc. Two-stage reconstituting injector
US9144648B2 (en) 2006-05-03 2015-09-29 Antares Pharma, Inc. Injector with adjustable dosing
WO2009114542A1 (en) 2008-03-10 2009-09-17 Antares Pharma, Inc. Injector safety device
ES2738539T3 (es) 2008-08-05 2020-01-23 Antares Pharma Inc Inyector de dosis múltiples
CA2755779C (en) 2009-03-20 2015-11-10 Antares Pharma, Inc. Hazardous agent injection system
EP2799071B1 (en) 2010-06-16 2018-10-17 Inflammatory Response Research, Inc. Levocetirizine and montelukast for the treatment of influenza and common cold
US8496619B2 (en) 2011-07-15 2013-07-30 Antares Pharma, Inc. Injection device with cammed ram assembly
US9220660B2 (en) 2011-07-15 2015-12-29 Antares Pharma, Inc. Liquid-transfer adapter beveled spike
FI2822618T3 (fi) 2012-03-06 2024-03-21 Antares Pharma Inc Esitäytetty injektioruisku laukeamisvoimaominaisuuden kera
KR20150011346A (ko) 2012-04-06 2015-01-30 안타레스 팔마, 인코퍼레이티드 테스토스테론 조성물의 바늘-보조식 젯 주입 투여 장치 및 방법
WO2013169800A1 (en) 2012-05-07 2013-11-14 Antares Pharma, Inc. Injection device with cammed ram assembly
FI3659647T3 (fi) 2013-02-11 2024-03-28 Antares Pharma Inc Neula-avusteinen suihkuinjektiolaite, jolla on pienennetty liipaisinvoima
WO2014164786A1 (en) 2013-03-11 2014-10-09 Madsen Patrick Dosage injector with pinion system
WO2014165136A1 (en) 2013-03-12 2014-10-09 Antares Pharma, Inc. Constant volume prefilled syringes and kits thereof
JP2016512262A (ja) 2013-03-13 2016-04-25 インフラマトリー・レスポンス・リサーチ・インコーポレイテッド 血管炎の処置におけるレボセチリジン及びモンテルカストの使用
ES2660494T3 (es) 2013-03-13 2018-03-22 14779507 Uso de levocetirizina y montelukast en el tratamiento de una lesión traumática
EP3300734B1 (en) 2013-03-13 2019-08-14 Inflammatory Response Research, Inc. Use of levocetirizine and montelukast in the treatment of autoimmune disorders
JP2017526728A (ja) 2014-09-15 2017-09-14 インフラマトリー・レスポンス・リサーチ・インコーポレイテッド 炎症介在性状態の治療におけるレボセチリジン及びモンテルカスト

Family Cites Families (7)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5571499A (en) * 1987-06-24 1996-11-05 Autoimmune, Inc. Treatment of autoimmune diseases by aerosol administration of autoantigens
ATE130762T1 (de) * 1987-06-24 1995-12-15 Autoimmune Inc Behandlung von autoimmun-erkrankungen durch orale verabreichung von autoantigenen.
US5571500A (en) * 1987-06-24 1996-11-05 Autoimmune, Inc. Treatment of autoimmune diseases through administration by inhalation of autoantigens
JPH05507501A (ja) * 1990-09-06 1993-10-28 リックスウーニーベルシテイト・テ・ウットレヒト リンパ球応答と免疫関連疾患との阻害剤
CA2117492C (en) * 1992-02-28 2009-04-07 Howard L. Weiner Bystander suppression of autoimmune diseases
AU5960096A (en) * 1995-06-07 1996-12-30 Nexstar Pharmaceuticals, Inc. Method to use superantigens to target subpopulations of t ce lls
DE69627855T2 (de) * 1995-06-13 2004-03-11 Nippon Meat Packers, Inc. Orales mittel gegen rheumatische arthritis und funktionelles nahrungsmittel

Also Published As

Publication number Publication date
CA2278152A1 (en) 1998-07-30
IL131025A0 (en) 2001-01-28
JP2001511134A (ja) 2001-08-07
HUP0001960A2 (hu) 2000-10-28
AU6648898A (en) 1998-08-18
NO993600L (no) 1999-09-23
KR20000070460A (ko) 2000-11-25
NO993600D0 (no) 1999-07-23
WO1998032451A1 (en) 1998-07-30
EP0994717A4 (en) 2000-07-26
EP0994717A1 (en) 2000-04-26

Similar Documents

Publication Publication Date Title
BR9807112A (pt) Composição, formulação farmacêutica, combinação e uso relacionados ao tratamento de doenças autoimunes utilizando antìgeno ou agente tolerante em combinação com metotrexato
BR0108435A (pt) Formulação e uso de entecavir de baixa dose
BR9106114A (pt) Metodo para tratar ou prevenir uma doenca auto-imune (ad) e formulacao farmaceutica
KR930702022A (ko) 인슐린의 경구 투여에 의한 타잎 1 당뇨병의 치료 또는 예방법
BR9811825A (pt) Uso de lactobacillus para redução do nìvel de fibrinogênio no sangue
BR9908030A (pt) Composição farmacêutica compreendendo uma ou mais unidades de dose oralmente ministráveis, e, processos para prepará-la, para uso da mesma, e para tratar uma condição ou distúrbio médico em um indivìduo em que tratamento com um inibidor da ciclooxigenase-2 é indicado
HUP9903732A2 (hu) cGMP-szintjét növelő szerek alkalmazása a jóindulatú prosztatatúltengés kezelésére szolgáló gyógyszerkészítmények előállítására
HUP0203556A2 (hu) Oxkarbazepint tartalmazó gyógyszerkészítmények és alkalmazásuk
HUP0101017A2 (hu) Készítmény és eljárás szájon át adagolható vakcinák és gyógyászati hatóanyagok szisztémás bevitelére
FR2719999B1 (fr) Composition pharmaceutique à base de gomme de guar et d'un antiacide neutralisant, à laquelle peut être ajoutée une série de principes actifs thérapeutiques.
ES2074698T3 (es) Composicion oral para el tratamiento de enfermedades intestinales inflamatorias.
BR9809951A (pt) Método para tratamento da obesidade
KR960700059A (ko) 파킨슨씨 병 및 파킨슨 중후군의 치료에 카르바마제핀 및 옥스카르바제핀의 이용(application of carbamazepine and oxcarbazepine in the treatment of parkinson's disease and parkinsonian syndromes)
BR9711194A (pt) Uso de agente quelante clioquinol para a fabricação de uma composição farmacêutica para o tratamento de doença de alzheimer.
BR9914631A (pt) Composição imunológica oral indutora de tolerância para prevenção e/ou tratamento de enfermidades e método para prevenção e/ou tratamento de enfermidades
CA2408537A1 (en) Treating irritable bowel syndrome or disease
DK1383752T3 (da) Deutererede 3-piperidinopropiophenoner samt lægemidler indeholdende disse forbindelser
SI1073456T1 (sl) Uporaba osteoprotegerina za preventivo pred kardiovaskularnimi boleznimi in za njihovo zdravljenje
BR0012444A (pt) Composições de pó seco
CA2433833A1 (en) Use of flumazenil in developing a drug for the treatment of alcohol dependence
BRPI0412430A (pt) polipeptìdeo agonista do receptor de zot e zonulina
ES2109234T3 (es) Metodo de tratamiento de la uveorretinitis autoinmune en el hombre.
NO943288L (no) Anvendelse av pentoksyfyllin ved fremstilling av farmasöytiske preparater til behandling av granulomatöse og fibroserende lungesykdommer
BR0207704A (pt) Alfa interferon modificado com imunogenicidade reduzida
BR0212249A (pt) Composto, composição farmacêutica, método de tratamento ou profilaxia de doenças, e, uso de um composto

Legal Events

Date Code Title Description
FA10 Dismissal: dismissal - article 33 of industrial property law
B11Y Definitive dismissal - extension of time limit for request of examination expired [chapter 11.1.1 patent gazette]